Comprehensive analysis of PSMG3 in pan-cancer and validation of its role in hepatocellular carcinoma
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03580-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Mengli Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China. Hauptthemen laut MEDLINE: Molecular Chaperones, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Dongguan Science and Technology of Social Development Program.
Abstract (Originalsprache)
BACKGROUND: Proteasome assembly chaperone 3 (PSMG3), a subunit of proteasome, has been found to be associated with lung cancer. However, the role of PSMG3 in other cancers has not been elucidated. The objective of this study was to explore the immune role of PSMG3 in pan-cancer and confirm the oncogenic significance in liver hepatocellular carcinoma (LIHC). METHODS: We examined the differential expression of PSMG3 across various cancer types using data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. We investigated the prognostic value of PSMG3 and examined its relationship with tumor mutation burden (TMB), microsatellite instability (MSI), and immune infiltration. The functional enrichment analysis was performed to explore the potential molecular mechanism of PSMG3. To elucidate the biological function of PSMG3, we conducted in vitro experiments using liver cancer cell lines. RESULTS: PSMG3 was highly expressed in most cancers. The high PSMG3 expression value of PSMG3 was closely related to poor prognosis. We observed correlations between PSMG3 and TMB, and MSI immune infiltration. PSMG3 may be involved in metabolic reprogramming, cell cycle, and PPAR pathways. The over-expression of PSMG3 promoted the proliferation, migration, and invasion capabilities of liver cancer cells. CONCLUSION: Our study demonstrated that PSMG3 was a pivotal oncogene in multiple cancers. PSMG3 contributed to the progression and immune infiltration in pan-cancer, especially in LIHC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China.
- Department of Nephrology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
- Department of Gastroenterology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China. chen_gui_quan@126.com.
- Department of Gastroenterology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, China. caiby5@mail2.sysu.edu.cn.
Förderung
- Dongguan Science and Technology of Social Development Program
Zitieren
APA
Zheng, M., Chen, X., Xu, Z., Ye, Z., Zhong, L., Chen, Z., Chen, G., & Cai, B. (2024). Comprehensive analysis of PSMG3 in pan-cancer and validation of its role in hepatocellular carcinoma. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03580-8
Vancouver
Zheng M, Chen X, Xu Z, Ye Z, Zhong L, Chen Z, et al. Comprehensive analysis of PSMG3 in pan-cancer and validation of its role in hepatocellular carcinoma. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03580-8
BibTeX
@article{Zheng2024,
author = {Zheng, Mengli and Chen, Xiaochun and Xu, Zhe and Ye, Zhitao and Zhong, Lixian and Chen, Zhicao and Chen, Guiquan and Cai, Boyong},
title = {Comprehensive analysis of PSMG3 in pan-cancer and validation of its role in hepatocellular carcinoma},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03580-8}
}
EUVIMED